Kisunla (donanemab-azbt) / Eli Lilly - LARVOL DELTA

Successful Amyloid Removal by Donanemab Treatment in a Female Patient With Alzheimer Disease: A Case Report. (PubMed, Neurology) - No abstract available

Journal • Alzheimer's Disease • CNS Disorders

[AD/PD 2026] In Japan, donanemab shows benefits despite heavy clinical burden (Korea Biomedical Review) - "The Alzheimer's Disease Assessment Scale-Cognitive Subscale showed initial improvement in word recall in the treatment group, with a similar trend observed after increasing the sample size. The Clinical Dementia Rating-Sum of Boxes worsened overall, but domains such as judgment and problem solving and home and hobbies were relatively preserved, while orientation significantly declined. The pattern suggests that the clinical effects of lecanemab may emerge over time...Safety analyses from January 2024 to January 2026 showed that infusion-related reactions occurred in 11.1 percent of donanemab cases."

Real-world • Alzheimer's Disease

Comparison table: Drugs for Alzheimer's disease dementia. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Drugs for dementia. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Alzheimer's Disease • CNS Disorders • Dementia • Movement Disorders • Parkinson's Disease

Comparison table: Amyloid beta-directed antibodies for Alzheimer's disease. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Alzheimer's Disease • CNS Disorders • Dementia

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) (clinicaltrials.gov) - P3 | N=1500 | Recruiting | Sponsor: Eli Lilly and Company

New P3 trial • Alzheimer's Disease • CNS Disorders

Eligibility for lecanemab treatment in a French memory clinic setting. (PubMed, J Neurol) - "In specialized settings, lecanemab eligibility remained limited, highlighting the need for early AD diagnosis and efficient screening pathways."

Biomarker • Clinical • Journal • Observational data • Retrospective data • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • APOE

Efficacy and Safety of Donanemab in the Treatment of Alzheimer's Disease: A Systematic Review and Meta-Analysis. (PubMed, Curr Alzheimer Res) - "Donanemab provides statistically significant but modest benefits in early AD, particularly in low-tau subgroups. However, the magnitude of cognitive and functional improvement did not approach the threshold for a MCID in the overall population, which requires stringent safety monitoring for ARIA. Clinical implementation should prioritize PET stratification and APOEguided surveillance."

Journal • Retrospective data • Alzheimer's Disease • CNS Disorders

Patient Eligibility: Identifying Appropriate Patients for Kisunla® in Clinical Practice, and Clinical Case Addressing Challenges in Patient Management and Treatment Monitoring (ADPD 2026) - "Supported by Eli Lilly and Company."

Clinical • Alzheimer's Disease • CNS Disorders

BRAIN-WIDE QUANTIFICATION OF BBB-CROSSING ANTIBODY THERAPEUTICS IN AD MODEL MICE (ADPD 2026) - "These findings demonstrate the utility of our integrated tissue clearing and analysis platform for monitoring BBB penetration, biodistribution, and target engagement across the entire brain."

Preclinical • Alzheimer's Disease • CNS Disorders • TFRC

NEXT GENERATION WISIT VACCINES DIRECTED AGAINST PATHOLOGIC FORMS OF ASS INDUCE POTENT ANTIBODY RESPONSES MIRRORING APPROVED MONOCLONAL ANTIBODIES (ADPD 2026) - "Our studies provide proof-of-concept for the efficacy of Ab targeting WISIT AD vaccines and support further preclinical and clinical development of these vaccine candidates."

Alzheimer's Disease • CNS Disorders

REGIONAL AMYLOID BURDEN AND CLEARANCE ACROSS AD CLINICAL PHENOTYPES AFTER 6 MONTHS OF ANTI-AMYLOID THERAPY (ADPD 2026) - "Aims: To assess baseline amyloid burden and regional SUVR patterns across AD phenotypes and their changes after 6 months of anti-amyloid therapy. Twenty AD patients received lecanemab (n=8) or donanemab (n=12) for at least 6 months. Baseline and 6-month amyloid reduction varied by clinical phenotype. EOAD had higher baseline SUVRs. MCI had greater reductions than mild dementia."

Clinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • APOE

DEMOGRAPHIC, COGNITIVE, AND BIOMARKER PATTERNS IN MCI AND ALZHEIMER'S DISEASE (AD) AMONG PATIENTS INITIATING DONANEMAB IN THE REAL-WORLD (ADPD 2026) - "This Real-world evidence study provides demographic and diagnostic distributions to support safety and effectiveness analyses as well as guidance for more efficient paths to appropriate treatment."

Biomarker • Clinical • Real-world • Real-world evidence • Alzheimer's Disease • CNS Disorders • APOE

IDENTIFICATION OF A NOVEL ABETA(PGLU3-X) TARGETING PATHWAY IN ALZHEIMER'S DISEASE (ADPD 2026) - "Aims: Current approaches for AD therapy targeting Abeta(pGlu3-x) have focused on the inhibition of the enzyme glutaminyl cyclase (QC) to prevent Abeta(pGlu3-x) formation and on the clearance of existing Abeta(pGlu3-x) aggregates by passive immunization with monoclonal antibodies such as Donanemab... We conclude that the upregulation of PGP-1 activity might be considered as a therapeutic approach to reduce Abeta(pGlu3-x) load in AD."

Alzheimer's Disease • CNS Disorders

MONITORING AND PREDICTING AMYLOID THERAPY RESPONSE USING ARTERIAL SPIN LABELLING PERFUSION MRI (ADPD 2026) - "Aims: To monitor and predict anti-amyloid therapy outcomes using arterial spin labelling MRI. T1-weighted structural and PCASL images for 17 patients (7M 10F, aged 72.4 ± 7.5 years, 14 on lecanemab, 3 on donanemab), collected at baseline and during ARIA monitoring sessions on GE 3T scanners, were analysed. CBF measured with ASL MRI was found to correlate strongly with cognitive outcomes on amyloid therapy, and to predict outcomes after two months of treatment. This will enable a precision medicine approach to future treatment."

BASELINE CHARACTERISTICS AMONG EARLY INITIATORS OF DONANEMAB IN THE UNITED STATES: A REAL-WORLD STUDY (ADPD 2026) - "This cohort study provides insights into the early initiators of donanemab in routine care. Since the characteristics of the study population reflect the specific data source used, findings may not be broadly generalizable. Additional analyses of donanemab utilization and monitoring during follow-up will be presented at the conference."

Clinical • Real-world • Real-world evidence • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Dyslipidemia • Hypertension • Metabolic Disorders

THREE DISCRETE ASSEMBLIES OF DIFFUSIBLE AMYLOID-BETA FROM ALZHEIMER DISEASE BRAIN (ADPD 2026) - "Diffusible Aβ assemblies in AD brains exist predominantly as particulate entities. We identified a distinct MMW Aβ assembly enriched in diffuse-plaque regions and targeted by lecanemab and donanemab. These findings help characterize key diffusible Aβ species and linking plaque pathology to therapeutic targets in AD."

Alzheimer's Disease • CNS Disorders • Aβ42

NEURODEGENE 2.0: TARGETED NGS GENETIC VARIANT PANEL AND MACHINE LEARNING MODELS FOR DIFFERENTIAL DIAGNOSIS OF DEMENTIA (ADPD 2026) - P | "NeuroDeGene 2.0 translates broader genetic coverage into practical gains for early detection and differential diagnosis, while providing insights into the genetic underpinnings of NDs. By bringing disease-specific and cross-disease genetic variants into a single assay, it supports clinical triage and trial enrichment and fits pre-screening workflows for disease-modifying therapies such as lecanemab and donanemab. The potential for integration with other biomarkers, such as blood-based biomarkers and imaging, promises to further enhance its clinical utility."

Machine learning • Next-generation sequencing • Alzheimer's Disease • CNS Disorders • Dementia • APOE

CHRONOLOGICAL EVALUATION OF BRAIN CHANGES IN ALZHEIMER'S PATIENTS RECEIVING ANTI-AΒ TREATMENT WITH SYNTHETIC MRI (ADPD 2026) - "Aims: To investigate the effect of anti-Aβ therapy by quantifying annual brain volume changes using Synthetic MRI (SyMRI). Patients diagnosed with Alzheimer's disease (AD) and treated with Lecanemab or Donanemab were enrolled. SyMRI-based measurements showed low CV, indicating strong test-retest reliability. The annual decline in BPF matched rates previously reported for mild cognitive impairment patients and GM remained more stable than WM."

Clinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders

A GAS6-BASED FUSION PROTEIN (GAIA) ENABLING INFLAMMATION-SILENT CLEARANCE OF AMYLOID BETA AND MITIGATION OF ARIA RISK IN ALZHEIMER'S DISEASE (ADPD 2026) - "Approved antibody therapies, including lecanemab and donanemab, lower plaque burden and slow progression, yet their Fc-mediated effector functions can trigger neuroinflammation and amyloid-related imaging abnormalities (ARIA). By uncoupling IgG1 effector functions and harnessing TAM-driven efferocytosis, GAIA-Aβ lowers Aβ burden while minimizing neuroinflammation and ARIA risk. These findings position GAIA-Aβ as a differentiated therapeutic modality with the potential to overcome safety limitations of current anti-Aβ antibodies."

Alzheimer's Disease • CNS Disorders • Inflammation • AXL • GAS6 • MERTK

QUANTITATIVE SYSTEMS PHARMACOLOGY ANALYSES OF BETA-AMYLOID AGGREGATION DYNAMICS: ADDITIVE/SYNERGISTIC EFFECTS OF VALILTRAMIPROSATE USED IN COMBINATION WITH LEQEMBI AND KISUNLA (ADPD 2026) - "Valiltramiprosate acts upstream in the beta-amyloid cascade to prevent the formation of toxic soluble oligomers. Valiltramiprosate when used in combination with Leqembi or Kisunla offers potential additive and synergistic benefits that translate into reduction of oligomer, protofibril and/or plaque burden. The combination effects were dependent on APOE4 genotype and disease stage."

Combination therapy • Alzheimer's Disease • CNS Disorders • APOE

TREATMENT-RELATED RETENTION OF INSTRUMENTAL ACTIVITIES OF DAILY LIVING IN EARLY ALZHEIMER'S DISEASE: MODELING A-IADL STATUS AS A FUNCTION OF CDR-SB (ADPD 2026) - "This large dataset enables modeling of treatment benefits by linking CDR-SB scores to A-IADL function across a range of neurocogonitive status, from normal to moderate dementia, providing clinically relevant information regarding the real-world impact of disease modification in AD."

Alzheimer's Disease • CNS Disorders • Dementia

SIMULATING TRAILBLAZER-ALZ 2 WITH DIGITAL TWINS TO BOOST POWER FOR MCI SUBGROUPS AND SECONDARY ENDPOINTS (ADPD 2026) - "Incorporating digital twins as supercovariates improved power for MCI subgroup analyses in a simulated donanemab trial without increasing enrollment. This approach enhances sensitivity for detecting treatment effects, particularly in early-stage populations and secondary endpoints. Synthetic data generators further provide a versatile tool for optimizing trial design, including exploration of alternative eligibility criteria, thereby reducing the risk of underpowered results in early AD trials."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders

FLORBETABEN BINDING TO AMYLOID PLAQUES IS UNAFFECTED BY AMYLOID-TARGETING ANTIBODIES LECANEMAB AND DONANEMAB (ADPD 2026) - "These results demonstrate that neither lecanemab nor donanemab interfere with florbetaben binding to Aß plaques in vitro, which is further validating its use in this setting."

Alzheimer's Disease • CNS Disorders

PREDICTION OF A FUTURE CLINICAL DIAGNOSIS OF ALZHEIMER DISEASE BY ELECTRONIC HEALTH RECORDS DATA (ADPD 2026) - "An AD diagnosis was determined based on clinical notes or the use of AD-related medications (lecanemab and donanemab). AI methods can be successfully leveraged on routinely collected clinical data to develop effective early warning predictive models for AD, potentially improving patient outcomes, reducing healthcare costs, and supporting precision medicine through early diagnosis and access to interventions."

Clinical • Alzheimer's Disease • Cardiovascular • CNS Disorders • Hypertension